½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  1. »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹LIFR¶à¿Ë¡¿¹Ìå

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • Íÿ¹LIFR¶à¿Ë¡¿¹Ìå

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW11306
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º100ul/200ul/25ul
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·

    ÖÐÎÄÃû³Æ£º Íÿ¹LIFR¶à¿Ë¡¿¹Ìå

    Ó¢ÎÄÃû³Æ£º Anti-LIFR rabbit polyclonal antibody

    ±ð     Ãû£º SWS, SJS2, STWS, CD118, LIF-R

    Ïà¹ØÀà±ð£º Ò»¿¹

    ´¢     ´æ£º Àä¶³£¨-20¡æ£©

    ËÞ     Ö÷£º Rabbit

    ¿¹     Ô­£º LIFR

    ·´Ó¦ÖÖÊô£º Human

    ±ê ¼Ç Î Unconjugate

    ¿Ë¡ÀàÐÍ£º rabbit polyclonal

    ¼¼Êõ¹æ¸ñ

    Background:

    This gene encodes a protein that belongs to the type I cytokine receptor family. This protein combines with a high-affinity converter subunit, gp130, to form a receptor complex that mediates the action of the leukemia inhibitory factor, a polyfunctional cytokine that is involved in cellular differentiation, proliferation and survival in the adult and the embryo. Mutations in this gene cause Schwartz-Jampel syndrome type 2, a disease belonging to the group of the bent-bone dysplasias. A translocation that involves the promoter of this gene, t(5;8)(p13;q12) with the pleiomorphic adenoma gene 1, is associated with salivary gland pleiomorphic adenoma, a common type of benign epithelial tumor of the salivary gland. Multiple splice variants encoding the same protein have been found for this gene.

    Applications:

    ELISA, IHC

    Name of antibody:

    LIFR

    Immunogen:

    Synthetic peptide of human LIFR

    Full name:

    leukemia inhibitory factor receptor alpha

    Synonyms£º

    SWS, SJS2, STWS, CD118, LIF-R

    SwissProt:

    P42702

    ELISA Recommended dilution:

    1000-5000

    IHC positive control:

    Human colon cancer and Human ovarian cancer

    IHC Recommend dilution:

    25-100






    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿